Beigene (ONC) Stock Price, News & Analysis

Company Overview

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.

Key Stats

• Today's Range: $244.08 to $250.00
• 50-Day Range: N/A
• 52-Week Range: $126.97 to $287.88
• Volume: 620,569 shs
• Average Volume: 464,123 shs
• Market Capitalization: $24.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $327.00
• Consensus Rating: Buy

Beigene Stock Analysis - MarketRank™

Beigene scored higher than 41% of companies evaluated by MarketBeat, and ranked 616th out of 934 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Beigene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Beigene has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Beigene are expected to grow in the coming year, from ($5.82) to $0.71 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Beigene is -30.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Beigene is -30.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Beigene has a PEG Ratio of 7.73. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Beigene has a P/B Ratio of 6.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for ONC.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Beigene does not currently pay a dividend.

Dividend Growth

Beigene does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for ONC.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.18

News Sentiment

Beigene has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Beigene this week, compared to 11 articles on an average week.

MarketBeat Follows

3 people have added Beigene to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Beigene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $259,543,196.00 in company stock.

Percentage Held by Insiders

Only 7.43% of the stock of Beigene is held by insiders.

Percentage Held by Institutions

48.55% of the stock of Beigene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ONC Stock Analysis - Frequently Asked Questions

How have ONC shares performed this year?

Beigene's stock was trading at $223.50 at the beginning of the year. Since then, ONC shares have increased by 11.8% and is now trading at $249.84.
View the best growth stocks for 2025 here.

How were Beigene's earnings last quarter?

Beigene, Ltd. (NASDAQ:ONC) announced its earnings results on Thursday, February, 27th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by $0.55. The firm had revenue of $1.13 billion for the quarter, compared to analysts' expectations of $1.09 billion. Beigene had a negative trailing twelve-month return on equity of 25.12% and a negative net margin of 25.94%.

How do I buy shares of Beigene?

Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 2/27/2025
• Today: 3/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ONC
• Previous Symbol: NASDAQ:ONC
• CIK: 1651308
• Web: N/A
• Phone: 13459494123
• Fax: N/A
• Employees: 10,600
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $327.00
• High Stock Price Target: $348.00
• Low Stock Price Target: $313.00
• Potential Upside/Downside: +30.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.14)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 7.73
• Net Income: $-881,710,000.00
• Net Margins: -25.94%
• Pretax Margin: -24.07%
• Return on Equity: -25.12%
• Return on Assets: -14.95%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 1.93
• Quick Ratio: 1.72

Sales & Book Value

• Annual Sales: $3.81 billion
• Price / Sales: 6.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $37.10 per share
• Price / Book: 6.73

Miscellaneous

• Outstanding Shares: 97,859,000
• Free Float: 90,588,000
• Market Cap: $24.45 billion
• Optionable: N/A
• Beta: 0.65